Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.45 |
| ▸ | ITGAV | P06756 | 20/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007604 | 0.92 | ITGAV (0.48) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7012225 | 0.92 | ITGAV (0.48) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7009416 | 0.83 | ITGAV (0.41) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7007999 | 0.83 | ITGAV (0.52) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7571708 | 0.80 | SLC6A2 (0.32) | ITGB3ITGA2B | |
| SCHEMBL8483637 | 0.77 | ITGAV (0.47) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL8483640 | 0.75 | ITGAV (0.47) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7006995 | 0.74 | ITGAV (0.45) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7912469 | 0.74 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL8479505 | 0.73 | ITGAV (0.49) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | claimed |
| JP-2001524079-A | — | — | 2001-11-27 | — | — | JP | claimed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | claimed |
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-5952341-A | VITRONECTIN RECEPTOR ANTAGONISTS FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING RESTENOSIS, DIABETIC RETINOPATHY, TUMOR, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |